Gilead Sciences has posted topline results from three Phase III trials — ION 1, 2, and 3 — evaluating the investigational once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg and the NS5A inhibitor ledipasvir (LDV) 90 mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection. Across the three studies, 1,952 patients with genotype 1 HCV infection were randomized to receive SOF/LDV...